NVV1 trade ideas
Vaccine candidates seeing huge gains.A good trade to consider is vaccine development companies. Some of the major players are Novavax, Moderna and Giliad. A conservative price target might be 15-25%.
Novavax (NVAX): Tell me about my Schiff!I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is established and recurring. It fact, it's becoming more difficult to handle with every year. The strains are becoming more advanced and unpredictable. Whether or not Novavax can produce a profitable candidate, I simply don't know. I believe that their patented tech is promising.
Novavax might not produce a COVID vaccine before its competitors (or at all) but they continue to demonstrate their technology and approach works. Example: ir.novavax.com
That being said, tell me about this random Schiff I plotted :)
Matrix-M Adjuvant: novavax.com
NanoFlu Phase 3 topline data: novavax.com
RSV F Vaccine: novavax.com
Novavax Big Break Out Day!- $NVAX, +30.80% as it rallied after the biotech announced it received a large $384m investment for its COVID-19 vaccine candidate and beat Earnings expectations.
- Technically we are in a strong uptrend - just broken out of its corrective move down. This is the type of stock which may take off further quite quickly - we could wait for a pullback (possibly at the old highs) or buy this breakout at the open market. Will depend on your risk appetite.
- Targets have been set based on the Pitchforks and Median Line Theory.
NVAX - Setting up nicely for ShortWith 100% implied volatility - and 3 month options costing 225% of Implied Vol. You can safely bet on a short, soon you pick the top with your fav strategy.
Analysis -
This whole run up is for a huge offering.
Company has no cash or cash equivalent.
Upcoming obligations - $342k + unknown research cost and operating expenses.
If I read this correctly, About 4.9M shares are going to be dumped (Around $30 peak, or before) Soon will roll down. - Looking for 3 month mark.
secfilings.nasdaq.com
secfilings.nasdaq.com
NVAX great swing into earnings. Go long, tight stop. NASDAQ:NVAX is giving us a great swing trade setup. few days to print. VWAP, fast MA, med MA sitting above slow MA for a long time and offering up a beautiful retracement that will bounce off the indicators right before earnings. Go long, and set a stop where VWAP gets crossed down by the fast MA AND the med MA. Should bring a 4:1 profit to risk ratio.
NVAX Round UpNVAX has held its 13sma and is now looking to round up to reach its old high resistance level around the $24 range. I only plan on being in this until 4/30, due to earnings being reported after the bell
NVAX - Potential WAVE 1 of larger move up!See Descriptions on Chart.
We may be headed higher if resistance line is broken. I'll post additional screenshot of Momentum moving us lower before we go up again. Volume is not as high as we want to break the line just yet but we could just be catching our breath.
I'm staying on the sidelines on the long side until Resistance line is broken, but could be a decent shorting opportunity if we bounce off of resistance again.
Bullish Pennant on novavax 30 min chartLooks like Novavax is consolidating for a strong move upward. NASDAQ:NVAX
$NVAX Play The Break Out Above $18$NVAX is setting up as nice day trade if we get above $18 and the 52 week high of $18.25 a share. We could see $20 a share pretty easy, especially with the news out today.
MELBOURNE, Australia, April 16, 2020 /PRNewswire/ -- As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, at its Melbourne and Brisbane clinics within the coming weeks.
"Nucleus has a rich history of Phase 1 vaccine trials, and a long-standing track-record with Novavax (NVAX)," says Nucleus CEO Cameron Johnson. "This is the third confirmed global COVID19 vaccine trial and the first in Australia and we are well positioned to implement rapid testing with first-in-human trials over the coming weeks.
"With the capacity to conduct this trial across both our Melbourne and Brisbane clinics, we will be assisting Novavax to undertake Phase 1 trials and fast track NVX-CoV2373 to potential subsequent development as soon as possible," adds Johnson.
Novavax's early development efforts on vaccines for two other recent coronavirus epidemics – severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), along with prior work on Ebola (phase 1 trial conducted in Australia) – allows them to leverage their understanding of coronaviruses and adapt their research to create a vaccine for SARS-CoV-2, the virus that causes COVID-19.
"The urgent global race to develop a vaccine against the COVID-19 pandemic drove our rapid identification and selection of an optimal, highly immunogenic vaccine candidate," said Stanley C. Erck, President and CEO of Novavax. "We are pleased that Nucleus, our long-time partner, was able to accommodate our accelerated timeline."
The Phase 1 trial of NVX-CoV2373 is expected to begin in mid-May with preliminary immunogenicity and safety results in July.
The scale and absolute commitment to the highest standards make Nucleus the ideal partner in the rapid development of the vaccine for COVID-19.
"We own 150 of the total 250 dedicated phase I beds available in Australia over two sites in Melbourne and Brisbane, located within major medical precincts. Supported by our workforce of over 400 specialists, we are in the unique position of offering sponsors a multi-site pathway to conduct their clinical trials," says Johnson.
This scale allows Nucleus to address the urgency of the COVID-19 vaccine studies, without interruption to other ongoing clinical trials. The standards ensure the reliability of the studies, especially in the current pandemic situation across the world.
"For all of our clinical trials, Nucleus has implemented the highest level of Transmission-Based Precautions within its clinical units including the creation of dedicated teams of clinical staff," says Nucleus Infectious Diseases Physician and Microbiologist and, Associate Professor of Medicine at the University of Queensland, Dr Paul Griffin. "These staff are assigned to work only in functional designated areas and there is no cross-pollination of these teams, improving safety, reducing study risk, and ensuring integrity of the trials."
As a key partner in the development of these promising vaccine candidates, Nucleus' role in solving the current pandemic is top of mind for Johnson.
"As COVID-19 continues to impact the everyday life of all global citizens, finding a solution has become an urgent objective for governments and health organisations around the world. The world is watching and we're on the front line, supporting Novavax to unlock the potential of a Coronavirus COVID-19 vaccine."
Good luck to all!
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is.
Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains.
Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective.
I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time.
Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
Double top Wedge OverextensionI can feel the dump. We've formed a double top with this second leg creating a wedge as well as an over-extension of the Tenkan-sen. If not ripe for a reversal certainly a pullback--at least that's what I'm betting on.
Novavax $NVAX#Novavax hit the weekly 100SMA and stalling and forming double top. It may pull back on next week.
$NVAX long swing ideaReally sweet cup with handle set-up here in $NVAX. I'm long 200 @ $14.30 with $13.30 stop loss. Looking for a move back up to the recent highs near $17.70ish
$NVAX Novavax identifies COVID-19 VAccine Novavax, Inc. (NASDAQ: NVAX) today announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization. In addition, the already high microneutralization titers seen after one dose increased eight fold with a second dose. High titer microneutralizing antibodies are generally accepted evidence that a vaccine is likely to be protective in humans.
Source street insider
$NVAX Possible Gap FillMy only issue with the price action are these two candles highlighted in green. The April 3rd close of 15.61 is within the midranges of the real bodies both of which are positioned at two highest peaks of resistance during the buildup of this base in the 4.00 area. A fill to the upside will be very nice with this chart.
